bioRxivBioengineeringPreprint
Thermo-amplifier circuit in probiotic E. coli for stringently temperature-controlled release of a novel antibiotic
S. Dey, C. E. Seyfert, C. Fink-Straube, A. M. Kany, R. Mueller, S. Sankaran
Abstract
Peptide drugs have seen rapid advancement in biopharmaceutical development, with over 80 candidates approved globally. Despite their therapeutic potential, the clinical translation of peptide drugs is hampered by challenges in production yields and stability. Engineered bacterial therapeutics is a unique approach being explored to overcome these issues by using bacteria to produce and deliver therapeutic compounds at the body site of use. A key advantage of this technology is the possibility to control drug delivery within the body in real time using genetic switches. However, the performance of such genetic switches suffers when used to control drugs that require post-translational modifications or are toxic to the host. In this study, these challenges were experienced when attempting to establish a thermal switch for the production of a ribosomally synthesized and post-translationally modified peptide antibiotic, darobactin, in probiotic E. coli. These challenges were overcome by developing a thermo-amplifier circuit that combined the thermal-switch with a T7 RNA Polymerase and its promoter that overcame limitations imposed by the host transcriptional machinery due to its orthogonality to it. This circuit enabled production of pathogen-inhibitory levels of darobactin at 40{degrees}C while maintaining leakiness below the detection limit at 37{degrees}C. More impressively, the thermo-amplifier circuit sustained production beyond the thermal induction duration. Thus, raised temperature for 2 h was sufficient for the bacteria to produce pathogen-inhibitory levels of darobactin even in the physiologically relevant simulated conditions of the intestines that include bile salts and low nutrient levels. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=138 SRC="FIGDIR/small/579303v2_ufig1.gif" ALT="Figure 1"> View larger version (21K): org.highwire.dtl.DTLVardef@1cdb311org.highwire.dtl.DTLVardef@1a7523aorg.highwire.dtl.DTLVardef@77b68org.highwire.dtl.DTLVardef@136f52b_HPS_FORMAT_FIGEXP M_FIG C_FIG
- organism: E. coli
- assay: proteomics
- research focus: drug response / drug discovery
- approach: genetic perturbation / CRISPR
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Thermal shifts can override the effects of Transcription-targeting Antibiotics
Rahul Jagadeesan, Amir Mohammad Arsh, … Andre Sanches Ribeiro·bioRxiv·Oct 16, 2025
- Engineering Escherichia coli Nissle as safe chassis for delivery of therapeutic peptides
Aarón Pantoja‐Angles, Zahir Ali, … Magdy M. Mahfouz·bioRxiv·Aug 30, 2025
- Synthetic extremophiles: Species-specific formulations for microbial therapeutics and beyond.
M. Jimenez, J. L'Heureux, … G. Traverso·bioRxiv·Nov 30, 2022
- An antimicrobial peptide expression platform for targeting pathogenic bacterial species
Jack W. Rutter, Linda Dekker, … Chris P. Barnes·bioRxiv·Oct 9, 2023
- Nanoliter-scale selection of optimized bioengineered peptide antibiotics that rescue mice with bacterial lung infection
Nils Böhringer, Zerlina G. Wuisan, … Till F. Schäberle·bioRxiv·May 30, 2024
- Bacteriocin peer selection for the production of antibiotic selection free biotherapeutic pDNA
Mohamed El Bakkoury, Luz P. Gómez de Cadiñanos, Philippe Gabant·bioRxiv·Oct 23, 2023